Epidemology of Acute Kidney Injury in Diabetic Patients Infected With covid_19 In Assiut University Hospital
NCT05074797 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-10-12
Summary
The novel coronavirus SARS-CoV-2 was identified as the causative agent for a series of atypical respiratory diseases in Wuhan, China in December of 2019(.1) The disease termed COVID-19, was officially declared a pandemic by the World Health Organization on March 11, 2020. SARS-CoV-2 contains a single-stranded, positive-sense RNA genome surrounded by an extracellular membrane containing a series of spike glycoproteins resembling a crown.COVID-19 infection results in diverse symptoms and morbidity depending on individual genetics, ethnicity, age, and geographic location. In severe cases, COVID-19 pathophysiology includes destruction of lung epithelial cells, thrombosis, hypercoagulation, and vascular leak leading to sepsis.(2) COVID-19 risk factors include cardiovascular disease, hypertension, and diabetes.(2)
Conditions
- Acute Kidney Injury Due to covid_19
Interventions
- DIAGNOSTIC_TEST
-
laboratory
laboratory data
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
doaa DR rezk, master · University Hospital
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-10-01
- Primary Completion
- 2022-02-20
- Completion
- 2022-03-20
Countries
- Egypt
Study Locations
More Related Trials
-
Prevent Diabetic Kidney Disease Among Egyptians
NCT06071208 ·Status: NOT_YET_RECRUITING
-
Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
NCT03573102 ·Status: UNKNOWN ·Phase: PHASE4
-
Treatment of Patients With Diabetic Kidney Disease
NCT06187493 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Oxygen Therapy in Diabetic Kidney Disease
NCT06959485 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
NCT06528405 ·Status: RECRUITING ·Phase: PHASE2
-
Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
NCT05459701 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
NCT05735197 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
NCT06113900 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
NCT04385589 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
NCT06982079 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment
NCT01097681 ·Status: COMPLETED ·Phase: PHASE1
-
Niclosamide Role in Diabetic Nephropathy
NCT04317430 ·Status: COMPLETED ·Phase: PHASE3
-
Prediabetes in End Stage Renal Disease on Dialysis
NCT07337083 ·Status: COMPLETED
-
Canagliflozin in Patients With Acute Decompansted Heart Failure
NCT05364190 ·Status: COMPLETED ·Phase: PHASE3
-
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
NCT04853615 ·Status: UNKNOWN
-
Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
NCT06421870 ·Status: RECRUITING ·Phase: PHASE3
-
To Improve the Ability of Early Screening and Diagnosis in Patients With Diabetic Nephropathy
NCT05047471 ·Status: UNKNOWN
-
Dapagliflozin in Respiratory Failure in Patients With COVID-19
NCT04350593 ·Status: COMPLETED ·Phase: PHASE3
-
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
NCT07020377 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
NCT06441591 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Dapagliflozin in Patients With Critical Illness
NCT05558098 ·Status: COMPLETED ·Phase: PHASE3
-
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients
NCT07302464 ·Status: COMPLETED
-
Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.
NCT05966818 ·Status: UNKNOWN ·Phase: PHASE4
-
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
NCT05748925 ·Status: COMPLETED ·Phase: PHASE4
-
SGLT-2 Inhibitors in the Treatment of Ascites
NCT05999773 ·Status: ACTIVE_NOT_RECRUITING